iBio (IBIO) Stock Price, News & Analysis

Company Overview

iBio, Inc. (NYSE: IBIO) is a biopharmaceutical and contract development and manufacturing organization that employs proprietary plant-based expression systems to accelerate the discovery, development and production of complex proteins. Its FastPharming platform leverages transient expression in plant hosts to produce vaccines, monoclonal antibodies and therapeutic proteins with shortened development timelines. The company’s ibioCDMO division offers end-to-end services, including cell line engineering, process development, scale-up and fill/finish operations, tailored to both small biotech innovators and established pharmaceutical firms.

Headquartered in Bryan-College Station, Texas, iBio operates a fully integrated cGMP facility that supports activities from preclinical research through commercial manufacturing. The company’s plant-based approach is designed to provide flexible capacity, rapid scale-up and cost-effective production compared with traditional mammalian cell or microbial systems. iBio has applied its technology to infectious disease vaccines, immuno-oncology candidates and specialty biologics, collaborating with partners across North America, Europe and Asia.

Since its founding in 2008, iBio has advanced its proprietary expression and glycosylation enhancement technologies, forging strategic partnerships and in-licensing agreements to broaden its product pipeline. Early milestones included the successful demonstration of large-scale protein expression in plant hosts and the establishment of a dedicated manufacturing campus. Over time, iBio has expanded its capabilities to meet evolving global demand for rapid response vaccine manufacturing and specialized bioprocessing services.

Under the leadership of Chief Executive Officer Robert Kay, a veteran in bioprocess development and biologics manufacturing, iBio continues to invest in platform innovation and facility expansion. The company’s focus on flexible, plant-based production aims to address emergent public health challenges and to support its partners in bringing novel biologics from concept to commercial supply.

Key Stats

• Today's Range: $0.74 to $0.81
• 50-Day Range: $0.71 to $1.03
• 52-Week Range: $0.64 to $6.89
• Volume: 577,203 shs
• Average Volume: 867,316 shs
• Market Capitalization: $12.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.30
• Consensus Rating: Buy

iBio Stock Analysis - MarketRank™

iBio scored higher than 26% of companies evaluated by MarketBeat, and ranked 831st out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

iBio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

iBio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for iBio are expected to decrease in the coming year, from ($1.74) to ($2.05) per share.

Price to Book Value per Share Ratio

iBio has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for IBIO.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

iBio does not currently pay a dividend.

Dividend Growth

iBio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for IBIO.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 2 people have searched for IBIO on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

2 people have added iBio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, iBio insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.58% of the stock of iBio is held by insiders.

Percentage Held by Institutions

Only 7.90% of the stock of iBio is held by institutions.

IBIO Stock Analysis - Frequently Asked Questions

How have IBIO shares performed this year?

iBio's stock was trading at $2.45 at the start of the year. Since then, IBIO stock has decreased by 69.0% and is now trading at $0.7590.

How were iBio's earnings last quarter?

iBio, Inc. (NYSE:IBIO) issued its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.46) EPS for the quarter, meeting analysts' consensus estimates of ($0.46).

How do I buy shares of iBio?

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of iBio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that iBio investors own include Fastly (FSLY), Fortinet (FTNT), Snowflake (SNOW), Tesla (TSLA), Arbor Realty Trust (ABR) and Accenture (ACN).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 7/14/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:IBIO
• Previous Symbol: NYSE:IBIO
• CIK: 1420720
• Web: www.ibioinc.com
• Phone: 302-355-0650
• Fax: 302-356-1173
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for iBio: $4.30
• High Price Target: $5.00
• Low Price Target: $3.60
• Potential Upside/Downside: +466.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.91 million
• Net Margins: N/A
• Pretax Margin: -3,795.73%
• Return on Equity: -73.15%
• Return on Assets: -45.51%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 1.76
• Quick Ratio: 1.76

Sales & Book Value

• Annual Sales: $375 thousand
• Price / Sales: 33.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.41 per share
• Price / Book: 0.54

Miscellaneous

• Outstanding Shares: 16,519,000
• Free Float: 9,818,000
• Market Cap: $12.54 million
• Optionable: N/A
• Beta: 0.94